VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ intolerance of or allergy to ticagrelor or         │ intolerance of or allergy to ticagrelor or         │     100 │
│ prasugrel                                          │ prasugrel                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ history of any stroke, transient ischemic attack   │ history of any stroke, transient ischemic attack   │     100 │
│ or intracranial bleeding                           │ or intracranial bleeding                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ known intracranial neoplasm, intracranial          │ known intracranial neoplasm, intracranial          │     100 │
│ arteriovenous malformation or intracranial         │ arteriovenous malformation or intracranial         │         │
│ aneurysm                                           │ aneurysm                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ active bleeding, clinical findings, that in the    │ active bleeding, clinical findings, that in the    │     100 │
│ judgement of the investigator are associated with  │ judgement of the investigator are associated with  │         │
│ an increased risk of bleeding                      │ an increased risk of bleeding                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ fibrin-specific fibrinolytic therapy less than 24  │ fibrin-specific fibrinolytic therapy less than 24  │     100 │
│ h before randomization, non-fibrin-specific        │ h before randomization, non-fibrin-specific        │         │
│ fibrinolytic therapy less than 48 h before         │ fibrinolytic therapy less than 48 h before         │         │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ oral anticoagulation that cannot be safely         │ oral anticoagulation that cannot be safely         │     100 │
│ discontinued for the duration of the study         │ discontinued for the duration of the study         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ INR known to be greater than 1.5 at the time of    │ INR known to be greater than 1.5 at the time of    │     100 │
│ screening                                          │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ chronic renal insufficiency requiring dialysis     │ chronic renal insufficiency requiring dialysis     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ moderate or severe hepatic dysfunction (Child Pugh │ moderate or severe hepatic dysfunction (Child Pugh │     100 │
│ B or C)                                            │ B or C)                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ increased risk of bradycardia events (Sick Sinus,  │ increased risk of bradycardia events (Sick Sinus,  │     100 │
│ AV block grade II or III, bradycardia-induced      │ AV block grade II or III, bradycardia-induced      │         │
│ syncope)                                           │ syncope)                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ concomitant medical illness that in the opinion of │ concomitant medical illness that in the opinion of │     100 │
│ the investigator is associated with a life         │ the investigator is associated with a life         │         │
│ expectancy \< 1 year                               │ expectancy < 1 year                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ concomitant oral or i.v. therapy with strong CYP3A │ concomitant oral or i.v. therapy with strong CYP3A │     100 │
│ Inhibitors (e.g. ketoconazole, itraconazole,       │ Inhibitors (e.g. ketoconazole, itraconazole,       │         │
│ voriconazole, telithromycin, clarithromycin,       │ voriconazole, telithromycin, clarithromycin,       │         │
│ nefazodone, ritonavir, saquinavir, nelfinavir,     │ nefazodone, ritonavir, saquinavir, nelfinavir,     │         │
│ indinavir, atazanavir, grapefruit juice \> 1 L/d), │ indinavir, atazanavir, grapefruit juice > 1 L/d),  │         │
│ CYP3A substrates with narrow therapeutic indices   │ CYP3A substrates with narrow therapeutic indices   │         │
│ (e.g. cyclosporine, quinidine), or strong CYP3A    │ (e.g. cyclosporine, quinidine), or strong CYP3A    │         │
│ inducers (e.g. rifampin/rifampicin, phenytoin,     │ inducers (e.g. rifampin/rifampicin, phenytoin,     │         │
│ carbamazepine, dexamethason, phenobarbital ) that  │ carbamazepine, dexamethason, phenobarbital ) that  │         │
│ cannot be safely discontinued                      │ cannot be safely discontinued                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ no written informed consent                        │ no written informed consent                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ participation in another investigational drug      │ participation in another investigational drug      │     100 │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ previous enrolment in this study                   │ previous enrolment in this study                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ for women of childbearing potential no negative    │ for women of childbearing potential no negative    │     100 │
│ pregnancy test and no agree to use reliable method │ pregnancy test and no agree to use reliable method │         │
│ of birth control during the study                  │ of birth control during the study                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy, giving birth within the last 90 days,   │ Pregnancy, giving birth within the last 90 days,   │     100 │
│ or lactation                                       │ or lactation                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ inability to cooperate with protocol requirements  │ inability to cooperate with protocol requirements  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ known platelet count \< 100.000/μL at the time of  │ known platelet count < 100.000/µL at the time of   │      97 │
│ screening                                          │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ known anemia (hemoglobin \<10 g/dL) at the time of │ known anemia (hemoglobin <10 g/dL) at the time of  │      99 │
│ screening                                          │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ index event is an acute complication (\< 30 days)  │ index event is an acute complication (< 30 days)   │      99 │
│ of PCI                                             │ of PCI                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ≥1 doses of ticagrelor or prasugrel within 5 days  │ =1 doses of ticagrelor or prasugrel within 5 days  │      99 │
│ before randomisation                               │ before randomisation                               │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                    │   Score │
╞═══════════════════════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Major                                             │ no written informed consent                      │      12 │
├───────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                 │ index event is an acute complication (< 30 days) │      34 │
│                                                   │ of PCI                                           │         │
├───────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Hospitalization for an acute coronary syndrome    │ known intracranial neoplasm, intracranial        │      40 │
│ (ST-segment elevation myocardial infarction, non- │ arteriovenous malformation or intracranial       │         │
│ ST-segment elevation myocardial infarction or     │ aneurysm                                         │         │
│ unstable angina pectoris) with planned invasive   │                                                  │         │
│ strategy                                          │                                                  │         │
╘═══════════════════════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒═════════════════════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                               │ CHIA Criteria   │   Score │
╞═════════════════════════════════════════════════╪═════════════════╪═════════╡
│ INR known to be greater than 1.5 at the time of │ NA              │       3 │
│ screening                                       │                 │         │
╘═════════════════════════════════════════════════╧═════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 94
Average Levenshtein Ratio of individual lines: 87.8076923076923
OverAll Ratio: 90.90384615384616
